Bioporto A/S
CSE:BIOPOR

Watchlist Manager
Bioporto A/S Logo
Bioporto A/S
CSE:BIOPOR
Watchlist
Price: 1.466 DKK 2.23% Market Closed
Market Cap: 629.9m DKK

EV/EBIT
Enterprise Value to EBIT

-8.1
Current
-8.3
Median
3.7
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-8.1
=
Enterprise Value
556.5m DKK
/
EBIT
-69.1m DKK
Market Cap EV/EBIT
DK
Bioporto A/S
CSE:BIOPOR
629.9m DKK -8.1
FR
Pharnext SCA
OTC:PNEXF
6T USD -208 029.2
US
Abbvie Inc
NYSE:ABBV
378B USD 26.2
US
Amgen Inc
NASDAQ:AMGN
170.3B USD 29.6
US
Gilead Sciences Inc
NASDAQ:GILD
138.7B USD 14.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
131.5B USD 28.2
US
Epizyme Inc
F:EPE
94.1B EUR -522.6
AU
CSL Ltd
ASX:CSL
120B AUD 21.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
73.4B USD 12.3
US
Seagen Inc
F:SGT
39.3B EUR -55.4
NL
argenx SE
XBRU:ARGX
32.9B EUR -2 339.9
EBIT Growth EV/EBIT to Growth
DK
Bioporto A/S
CSE:BIOPOR
Average EV/EBIT: 22
Negative Multiple: -8.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -208 029.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
26.2
29%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.6
31%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.2
10%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.2
15%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -522.6 N/A N/A
AU
CSL Ltd
ASX:CSL
21.3
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.3
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 339.9 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-6.9
2-Years Forward
EV/EBIT
-5.7
3-Years Forward
EV/EBIT
N/A